相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Targeting pancreatic cancer by TAK-981: a SUMOylation inhibitor that activates the immune system and blocks cancer cell cycle progression in a preclinical model
Sumit Kumar et al.
GUT (2022)
SUMOylation inhibition enhances dexamethasone sensitivity in multiple myeloma
Li Du et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2022)
The reactome pathway knowledgebase 2022
Marc Gillespie et al.
NUCLEIC ACIDS RESEARCH (2022)
Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma
Yuen Lam Dora Ng et al.
NATURE COMMUNICATIONS (2022)
Genetic alterations of the SUMO isopeptidase SENP6 drive lymphomagenesis and genetic instability in diffuse large B-cell lymphoma
Markus Schick et al.
NATURE COMMUNICATIONS (2022)
Where We Stand With Precision Therapeutics in Myeloma: Prosperity, Promises, and Pipedreams
Darren Pan et al.
FRONTIERS IN ONCOLOGY (2022)
Activated SUMOylation restricts MHC class I antigen presentation to confer immune evasion in cancer
Uta M. Demel et al.
JOURNAL OF CLINICAL INVESTIGATION (2022)
Discovery of TAK-981, a First-in-Class Inhibitor of SUMO-Activating Enzyme for the Treatment of Cancer
Steven P. Langston et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
The IMiD target CRBN determines HSP90 activity toward transmembrane proteins essential in multiple myeloma
M. Heider et al.
MOLECULAR CELL (2021)
Sulfopin is a covalent inhibitor of Pin1 that blocks Myc-driven tumors in vivo
Christian Dubiella et al.
NATURE CHEMICAL BIOLOGY (2021)
A small-molecule SUMOylation inhibitor activates antitumor immune responses and potentiates immune therapies in preclinical models
Eric S. Lightcap et al.
SCIENCE TRANSLATIONAL MEDICINE (2021)
Therapeutic Potential of Targeting the SUMO Pathway in Cancer
Antti Kukkula et al.
CANCERS (2021)
Multiple Myeloma: Molecular Pathogenesis and Disease Evolution
Michael Heider et al.
ONCOLOGY RESEARCH AND TREATMENT (2021)
Targeting SUMO Signaling to Wrestle Cancer
Jessie S. Kroonen et al.
TRENDS IN CANCER (2021)
SUMO pathway inhibition targets an aggressive pancreatic cancer subtype
Alexander Biederstadt et al.
GUT (2020)
Silencing of SENP2 in Multiple Myeloma Induces Bortezomib Resistance by Activating NF-κB Through the Modulation of IκBα Sumoylation
Hongyi Xie et al.
SCIENTIFIC REPORTS (2020)
Function of PIN1 in Cancer Development and Its Inhibitors as Cancer Therapeutics
Ji Hoon Yu et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2020)
SynergyFinder 2.0: visual analytics of multi-drug combination synergies
Aleksandr Ianevski et al.
NUCLEIC ACIDS RESEARCH (2020)
Multiple myeloma current treatment algorithms
S. Vincent Rajkumar et al.
BLOOD CANCER JOURNAL (2020)
Ubiquitination and Ubiquitin-Like Modifications in Multiple Myeloma: Biology and Therapy
Matthias Wirth et al.
CANCERS (2020)
The SUMO Isopeptidase SENP6 Functions as a Rheostat of Chromatin Residency in Genome Maintenance and Chromosome Dynamics
Kristina Wagner et al.
CELL REPORTS (2019)
Deregulation and Targeting of TP53 Pathway in Multiple Myeloma
Katarina K. Jovanovic et al.
FRONTIERS IN ONCOLOGY (2019)
SUMO-specific proteases and isopeptidases of the SENP family at a glance
Kathrin Kunz et al.
JOURNAL OF CELL SCIENCE (2018)
Drug resistance in multiple myeloma
Pawel Robak et al.
CANCER TREATMENT REVIEWS (2018)
Prolyl isomerase Pin1: a promoter of cancer and a target for therapy
Yang Chen et al.
CELL DEATH & DISEASE (2018)
Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation
Ivo A. Hendriks et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2017)
Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation
Ivo A. Hendriks et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2017)
Multiple myeloma
Shaji K. Kumar et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
The proteasome and proteasome inhibitors in multiple myeloma
Sara Gandolfi et al.
CANCER AND METASTASIS REVIEWS (2017)
SENP1 deSUMOylates and Regulates Pin1 Protein Activity and Cellular Function (vol 73, pg 3951, 2013)
C-H Chen et al.
CANCER RESEARCH (2017)
SUMO and the robustness of cancer
Jacob-Sebastian Seeler et al.
NATURE REVIEWS CANCER (2017)
Mapping the SUMOylated landscape
Karolin Eifler et al.
FEBS JOURNAL (2015)
Pin1-Induced Proline Isomerization in Cytosolic p53 Mediates BAX Activation and Apoptosis
Ariele Viacava Follis et al.
MOLECULAR CELL (2015)
Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunits
Diego Acosta-Alvear et al.
ELIFE (2015)
SENP1 deSUMOylates and Regulates Pin1 Protein Activity and Cellular Function
Chun-Hau Chen et al.
CANCER RESEARCH (2013)
Regulation of DNA Damage Responses by Ubiquitin and SUMO
Stephen P. Jackson et al.
MOLECULAR CELL (2013)
Pin1 modulates p63α protein stability in regulation of cell survival, proliferation and tumor formation
C. Li et al.
CELL DEATH & DISEASE (2013)
A Small Molecule Inhibitor of Ubiquitin-Specific Protease-7 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Bortezomib Resistance
Dharminder Chauhan et al.
CANCER CELL (2012)
Molecular signatures database (MSigDB) 3.0
Arthur Liberzon et al.
BIOINFORMATICS (2011)
Bortezomib-induced BRCAness sensitizes multiple myeloma cells to PARP inhibitors
Paola Neri et al.
BLOOD (2011)
A Pin1/Mutant p53 Axis Promotes Aggressiveness in Breast Cancer
Javier E. Girardini et al.
CANCER CELL (2011)
SUMOylation and de-SUMOylation in response to DNA damage
Hong Dou et al.
FEBS LETTERS (2011)
MEDICAL PROGRESS Multiple Myeloma
Antonio Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome
James J. Driscoll et al.
BLOOD (2010)
The Origins and Evolution of the p53 Family of Genes
Vladimir A. Belyi et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2010)
Conservation of DNA-binding specificity and oligomerisation properties within the p53 family
Tobias Brandt et al.
BMC GENOMICS (2009)
Improved survival in multiple myeloma and the impact of novel therapies
Shaji K. Kumar et al.
BLOOD (2008)
The prolyl isomerase Pin1 orchestrates p53 acetylation and dissociation from the apoptosis inhibitor iASPP
Fiamma Mantovani et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2007)
Protein kinase C β and prolyl isomerase 1 regulate mitochondrial effects of the life-span determinant p66Shc
Paolo Pinton et al.
SCIENCE (2007)
Ubiquitin and ubiquitin-like modifications of the p53 family
Ian R. Watson et al.
NEOPLASIA (2006)
Prognostic value of cyclin D2 mRNA expression in newly diagnosed multiple myeloma treated with high-dose chemotherapy and tandem autologous stem cell transplantations
I. Hanamura et al.
LEUKEMIA (2006)
The protein stability and transcriptional activity of p63 alpha are regulated by SUMO-1 conjugation
P Ghioni et al.
CELL CYCLE (2005)
SUMO:: a regulator of gene expression and genome integrity
S Müller et al.
ONCOGENE (2004)
Altered sumoylation of p63α contributes to the split-hand/foot malformation phenotype
YP Huang et al.
CELL CYCLE (2004)
Pin1 links the activities of c-Abl and p300 in regulating p73 function
F Mantovani et al.
MOLECULAR CELL (2004)
TP53 family members and human cancers
J Bénard et al.
HUMAN MUTATION (2003)
Members of the PIAS family act as SUMO ligases for c-Jun and p53 and repress p53 activity
D Schmidt et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Covalent modification of p73α by SUMO-1 -: Two-hybrid screening with p73 identifies novel SUMO-1-interacting proteins and a SUMO-1 interaction motif
A Minty et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
分享论文
